ResTORbio (NASDAQ:TORC) initiates a randomized placebo-controlled study evaluating RTB101 for the prevention of COVID-19 infection in nursing home residents.
The company will collaborate with investigators at
Brown University and privately held Insight Therapeutics, LLC on the
trial which will be conducted in certain facilities within the Genesis
Healthcare system.
According to the company, RTB101 is an oral,
selective and potent TORC1 inhibitor that inhibits the phosphorylation
of multiple targets downstream of TORC1. Inhibition of TORC1 has been
observed to extend lifespan and healthspan in aging preclinical species
and improve the function of aging organ systems, including the immune
system and central nervous system, suggesting potential benefits in
several aging-related diseases.
https://seekingalpha.com/news/3578205-restorbio-launches-study-of-rtb101-for-preventing-covidminus-19-in-nursing-homes
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.